 The studies measured the change from baseline in the frequency of convulsive seizures.In both studies, subjects treated with fenfluramine had significantly greater reductions in the frequency of convulsive seizures during the trials than subjects who received placebo (inactive treatment).These reductions were seen within 3–4 weeks, and remained generally consistent over the 14- to 15-week treatment periods.